Celladon Shares May Have Upside to $70
The developer of gene therapy for heart failure to announce pivotal trial results.
have good weekend
4:29 P.M. EST
CyberArk Software, Ltd. (NASDAQ:CYBR)
The IDC MarketScape assesses vendors offering products in the privileged access administration(PAM)market and notes that, “CyberArk is the “big gorilla” with the most proceed and largest customer base.”
Three trades to go before the closing bell
Friday, 20 Mar 2015 | 2:04 PM ET
Jon Najarian was a buyer of biotech stock ZIOP.
right on his tweets